Department of Pharmacology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Kidney Int. 2021 Jul;100(1):14-16. doi: 10.1016/j.kint.2021.04.030.
Hanudel et al. investigated the effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PHIs) on iron metabolism in a chronic kidney disease (CKD) mouse model and showed that vadadustat, an HIF-PHI, exerted beneficial effects on anemia and iron disorders independently of erythroferrone. Vadadustat also inhibited the progression of CKD and the CKD-associated increase of plasma fibroblast growth factor 23 in CKD mice. This study provides new insights into the action of HIF-PIHs in CKD.
汉德尔等人在慢性肾脏病（CKD）小鼠模型中研究了缺氧诱导因子脯氨酰羟化酶结构域抑制剂（HIF-PHIs）对铁代谢的影响，结果表明 HIF-PHI 类药物vadadustat 可通过不依赖红细胞生成素的方式对贫血和铁代谢紊乱产生有益作用。vadadustat 还可抑制 CKD 小鼠的 CKD 进展以及 CKD 相关的血浆成纤维细胞生长因子 23 增加。本研究为 HIF-PHIs 在 CKD 中的作用提供了新的见解。
